These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15342005)

  • 1. Recent developments in prion immunotherapy.
    Heppner FL; Aguzzi A
    Curr Opin Immunol; 2004 Oct; 16(5):594-8. PubMed ID: 15342005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie.
    Nitschke C; Flechsig E; van den Brandt J; Lindner N; Lührs T; Dittmer U; Klein MA
    Vet Microbiol; 2007 Aug; 123(4):367-76. PubMed ID: 17499458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection.
    Polymenidou M; Heppner FL; Pellicioli EC; Urich E; Miele G; Braun N; Wopfner F; Schätzl HM; Becher B; Aguzzi A
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14670-6. PubMed ID: 15292505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic effect of anti-PrP monoclonal antibodies in transmissible spongiform encephalopathy mouse models: pharmacokinetic and pharmacodynamic analysis.
    Féraudet-Tarisse C; Andréoletti O; Morel N; Simon S; Lacroux C; Mathey J; Lamourette P; Relaño A; Torres JM; Créminon C; Grassi J
    J Gen Virol; 2010 Jun; 91(Pt 6):1635-45. PubMed ID: 20107012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.
    Nikles D; Bach P; Boller K; Merten CA; Montrasio F; Heppner FL; Aguzzi A; Cichutek K; Kalinke U; Buchholz CJ
    J Virol; 2005 Apr; 79(7):4033-42. PubMed ID: 15767405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
    Moroncini G; Kanu N; Solforosi L; Abalos G; Telling GC; Head M; Ironside J; Brockes JP; Burton DR; Williamson RA
    Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10404-9. PubMed ID: 15240877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses.
    Hedlin PD; Cashman NR; Li L; Gupta J; Babiuk LA; Potter AA; Griebel P; Napper S
    Vaccine; 2010 Jan; 28(4):981-8. PubMed ID: 19925901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
    Perrier V; Solassol J; Crozet C; Frobert Y; Mourton-Gilles C; Grassi J; Lehmann S
    J Neurochem; 2004 Apr; 89(2):454-63. PubMed ID: 15056288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion protein-specific antibodies-development, modes of action and therapeutics application.
    Rovis TL; Legname G
    Viruses; 2014 Oct; 6(10):3719-37. PubMed ID: 25275428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases.
    Tayebi M; Hawke S
    Immunol Lett; 2006 Jun; 105(2):123-6. PubMed ID: 16621033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.
    Filesi I; Cardinale A; Mattei S; Biocca S
    J Neurochem; 2007 Jun; 101(6):1516-26. PubMed ID: 17542810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More tools for prion research.
    Bradbury J
    Drug Discov Today; 2004 Oct; 9(19):821-2. PubMed ID: 15381128
    [No Abstract]   [Full Text] [Related]  

  • 14. Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity.
    Müller-Schiffmann A; Petsch B; Leliveld SR; Muyrers J; Salwierz A; Mangels C; Schwarzinger S; Riesner D; Stitz L; Korth C
    Mol Immunol; 2009 Feb; 46(4):532-40. PubMed ID: 18973947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge.
    Fernandez-Borges N; Brun A; Whitton JL; Parra B; Diaz-San Segundo F; Salguero FJ; Torres JM; Rodriguez F
    J Virol; 2006 Oct; 80(20):9970-6. PubMed ID: 17005675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine approaches to prevent and treat prion infection : progress and challenges.
    Müller-Schiffmann A; Korth C
    BioDrugs; 2008; 22(1):45-52. PubMed ID: 18215090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies.
    Bade S; Frey A
    Expert Rev Vaccines; 2007 Apr; 6(2):153-68. PubMed ID: 17408366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping of possible prion protein self-interaction domains using peptide arrays.
    Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
    BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of two immunogenic domains of the prion protein--PrP--which activate class II-restricted T cells and elicit antibody responses against the native molecule.
    Gregoire S; Logre C; Metharom P; Loing E; Chomilier J; Rosset MB; Aucouturier P; Carnaud C
    J Leukoc Biol; 2004 Jul; 76(1):125-34. PubMed ID: 15075357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.